SHR-1905

DRUG2 trials

Sponsors

Atridia Pty Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions

Asthma

Phase 1

A Trial of SHR-1905 in Healthy Subjects

CompletedNCT04800263

Atridia Pty Ltd.Asthma

Start: 2021-07-27End: 2022-11-12Updated: 2023-05-10

Phase 2

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Active, not recruitingNCT05593250

Shanghai Hengrui Pharmaceutical Co., Ltd.Asthma

Start: 2023-01-17End: 2026-12-30Updated: 2026-06-05

Related Papers

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects

Frontiers in Pharmacology2024-07-156 citations